Answers are grounded in this paper and cite their sources.
Incorporating ctDNA monitoring along with traditional known risk factors may aid in identifying patients with stage I EC who are at highest risk of recurrence, and possibly aid in treatment stratification.
No takes yet. Share an insight, caveat, or question.
Recio et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: